Treating Obesity Without Judgement: What GLP-1 Medications Are Revealing About Us

The conversation around obesity has always been emotionally charged. But the recent attention on GLP-1 medications has exposed something deeper than disagreement about treatment. It has revealed a contradiction that many of us have been carrying, often without realising it.

We say obesity is a disease.

Yet we still treat it like a moral failing.

We acknowledge that genetics, biology, and environment play powerful roles.

Yet when someone seeks treatment, judgement quickly follows.

This tension has become impossible to ignore.

When health is moralised, people often carry judgement long before they ever seek care.

Two Stigmas, Not One

What has become increasingly clear is that we are dealing with two overlapping stigmas.

The first is the stigma of obesity itself. The assumption that excess weight reflects laziness, lack of discipline, or poor character. The idea that if someone truly “tried harder,” the problem would resolve.

The second is newer, but no less potent: the stigma of treating obesity.

When individuals pursue medical treatment, particularly GLP-1 therapies, they are often judged again. This time not for having obesity, but for addressing it “the wrong way.” Treatment is framed as cheating, vanity, or weakness. The goalposts shift. The judgement never really stops.

This reveals something uncomfortable. For many people, obesity is only acceptable if it is endured quietly. Attempts to treat it disrupt deeply ingrained beliefs about effort, virtue, and control.

Obesity Is Biology, Not a Moral Test

From a scientific perspective, obesity is not mysterious, and it is certainly not a character flaw.

It reflects the interaction between genetic predisposition and a modern environment that strongly influences appetite regulation, energy expenditure, insulin sensitivity, adipose tissue biology, and inflammatory signalling. These are real, measurable physiological processes.

This same biology underpins conditions we readily accept as medical diseases: type 2 diabetes, cardiovascular disease, fatty liver disease, and even certain cancers. We do not tell people with these conditions to simply “try harder.” We treat them.

Obesity deserves the same lens.

What GLP-1 Medications Actually Do

GLP-1 therapies do not bypass biology. They engage with it.

Used appropriately, they influence appetite regulation, satiety signalling, gastric emptying, and energy balance. In this way, they are no more a shortcut than metformin is for diabetes or statins are for atherosclerosis. They target underlying physiology.

And yet, the reaction to these medications is often visceral. People see weakness where treatment exists. They project moral narratives onto biological problems.

That reaction says far more about our cultural discomfort with obesity than it does about the medications themselves.

Medical treatment engages biology, not character, and should be understood in that context.

Why the Moralising Matters

Judgement has consequences.

When obesity is framed as a personal failure, people internalise shame. When treatment is framed as cheating, people delay care or avoid it entirely. Many have already tried countless approaches over decades. Nutrition plans. Exercise programs. Lifestyle changes. Often with short-term success followed by regain, not due to lack of effort, but due to physiology reasserting itself.

Dismissing treatment with phrases like “people should just try harder” ignores both evidence and lived experience.

Nuance Matters

None of this means GLP-1 therapies are for everyone.

Indications matter. Oversight matters. Long-term thinking matters. Nutrition, resistance training, sleep, and movement remain foundational. Medications do not replace these pillars, they may support them in selected individuals.

This is not an argument for universal use. It is an argument for intellectual honesty.

Healthcare decisions should be guided by evidence, physiology, and individual context, not moral judgement.

When judgement is removed, space opens for nuance, compassion, and better decisions.

What This Moment Is Really Teaching Us

The current debate is less about medications and more about how we think.

It asks whether we are willing to accept obesity as a disease in practice, not just in theory. Whether we can hold complexity without defaulting to judgement. Whether we can separate treatment from moral worth.

If we truly care about long-term health, dignity, and outcomes, we need to move beyond simplistic narratives. Obesity is not a test of character. Treating it is not a failure of willpower.

It is medicine engaging with biology.